An Open Label Trial to Evaluate the Efficacy and Safety of PRAX-628 in Adults With Focal Onset or Tonic-Clonic Seizures
← catalyst calendarSponsored by Praxis Precision Medicines (industry) · PRAX — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
50estimated
Sites
11
Countries
Australia, Spain, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-01-10 | actual | When the study began enrolling |
| Primary completion | Jul 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-04-03 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Focal Onset Seizure
- Primary Generalized Epilepsy
Intervention
- Drug: 30mg PRAX-628
Primary outcome
what the primary-completion date above is the date OFTo evaluate the efficacy of PRAX-628 on seizure frequency in adults with FOS or PGTCS currently taking ASMs
measured 8 weeks
Permalink · PRAX's whole pipeline · Catalyst calendar · Every registered study · What changed